Is my supplement label missing anything FDA requires?

This is United States federal law for dietary supplements. Two different bodies of rule govern your label, and a free checklist only knows about one of them.

The first is the labeling rules — 21 CFR part 101 and the misbranding provisions of the Act behind it. A generator can check some of those, and if that is all you are asking, a generator is a reasonable first pass.

The second is 21 CFR part 111, the manufacturing rule, and it never looks at the panel. It asks whether your records control the label that went on the bottle. That is the half no checklist can see, and it is where the inspection findings are.

On this page: What has to be on the panel · The claims layer, which is neither · The half a checklist cannot see · What FDA actually writes up · Why the panel rules do not appear · Four things to check

What has to be on the panel

This list is not exhaustive, and no list on a web page is. It is the set that catches the most labels, in the order a reader can check them.

• A statement of identity on the principal display panel, as one of its principal features, in bold type, sized in relation to the most prominent printed matter on the panel, in lines generally parallel to the base as the package is designed to be displayed (21 CFR 101.3(a), 101.3(d)). It must include the term “dietary supplement”, though “dietary” may be replaced by the name of a dietary ingredient (101.3(g)). A supplement whose labeling fails to use that term is misbranded (21 U.S.C. 343(s)(2)(B)).
• Net quantity of contents on the principal display panel, in weight, measure, numerical count or a combination (101.7(a)). A packaged food without an accurate quantity statement is misbranded on the face of the statute (343(e)).
• The ingredient list, by common or usual name, in descending order of predominance by weight. For a supplement the placement is fixed: immediately below the Supplement Facts panel, or contiguous and to its right where there is no room below, headed “Ingredients” — or “Other ingredients” where sources are already identified inside the panel. Non-dietary ingredients such as excipients, fillers, colors, sweeteners, flavors and binders belong in that list (101.4(g)). The general food rule at 101.4(a)(1) is not the one that governs here, and it permits placements this clause does not.
• Allergen declaration. Where the product contains a major food allergen, either the word “Contains” followed by the food source, printed immediately after or adjacent to the ingredient list in type no smaller than the list, or the source named in the list itself (343(w)(1)). This is the omission that turns into a recall rather than a letter.
• The name and place of business of the manufacturer, packer or distributor, conspicuously, with street address, city, state and ZIP — the street address may be omitted where it appears in a current city or telephone directory (101.5(a), 101.5(d)).
• A domestic address or domestic phone number through which a serious adverse event report can be received. This is a separate obligation from the name and place of business, and satisfying 101.5 does not discharge it (343(y)).
• Supplement Facts, unless an exemption reaches your product (101.36(a)). It carries “Serving Size” and “Servings Per Container” as subheadings (101.36(b)(1)(i), (b)(1)(ii)); ingredients with an RDI or DRV are declared one way (101.36(b)(2)), and those without are declared by common or usual name in their own part of the panel (101.36(b)(3)(i)).
• The part of the plant, for any botanical dietary ingredient. Failing to identify it makes the supplement misbranded (343(s)(2)(C)).
• Type size. Everything other than the title, headings and footnotes in uniform type no smaller than 8 point, with 6 point permitted for column headings and footnotes (101.36(e)).
• Warnings where they are triggered — for example the iron statement required on a solid oral dosage form containing iron or iron salts as an iron source (101.17(e)(1)).

Source ingredients may be shown inside the panel, in parentheses after the dietary ingredient or indented beneath it, preceded by “as” or “from”. That is an option, not a requirement — and where you do not take it, the source ingredient shall be listed in the ingredient statement under 101.4(g) instead (101.36(d)).

The claims layer, which is neither

A structure/function statement carries its own conditions, and they are not on either list above. The manufacturer must hold substantiation that the statement is truthful and not misleading; the label must carry the disclaimer — “This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease” — prominently displayed and in boldface (343(r)(6)(B), 343(r)(6)(C)); the disclaimer sits adjacent to the statement with no intervening material, or is linked to it by a symbol, boxed where it is not adjacent, on each panel or page carrying such a statement (101.93(d)); and the Secretary must be notified no later than 30 days after first marketing with the statement (101.93(a)(1)).

And a claim that crosses into disease territory takes the product out of the supplement framework entirely: a product marketed as a supplement whose labeling bears a disease claim is regulated as a drug unless the claim is an authorized health claim it qualifies for (101.93(f)). Where your product sits on that line is a category question before it is a label question.

The half a checklist cannot see

Part 111 asks a different question. Not what the label says — whether your records control it.

• Label specifications. You must establish specifications for supplement labels, and for packaging that may come in contact with the product; that packaging must be safe and suitable for its intended use and not reactive, absorptive, or otherwise affecting safety or quality (21 CFR 111.70(d)).
• A representative label in the master manufacturing record — a description of the packaging and a representative label, or a cross-reference to where the actual or representative label is held (111.210(g)).
• Written procedures for packaging and labeling operations, established and followed (111.403), with records kept of them (111.430(b)).
• Specifications for the finished packaged and labeled product, including specifications that ensure you used the specified packaging and applied the specified label (111.70(g)).
• Control of label issuance and use, and reconciliation of any discrepancy between what was issued and what was used (111.410(b)).
• Examination of labels before labeling operations, for each batch, to determine whether they conform to the master manufacturing record (111.410(c)). This is the clause that asks whether the right label went on.
• An actual or representative label in the batch production record (111.260(k)(2)), and a batch, lot or control number on each lot of packaged and labeled product (111.415(f)(1)).
• Traceability — the complete manufacturing history and control of the packaged and labeled product through distribution (111.410(d)).

None of that is visible on the panel. A correct label with no specification behind it, no representative label in the master record and no written labeling procedure is a compliant panel on an uncontrolled process, and it is the process that gets inspected.

What FDA actually writes up

FDA’s published inspection observation record contains no citations under 21 CFR part 101 at all. Not a small number. None. The panel rules are enforced through warning letters and misbranding actions, which are a different mechanism from an inspection observation.

What that record does contain, across the clauses that govern label control, is 1,108 observations:

Counted from FDA’s published inspection observation records, read August 17, 2026. Fiscal year 2026 was still open at that date. These are counts of clause citations in inspection observations, one row per citation, not counts of firms or inspections, and not counts of warning letters. The clause selection is ours.

Why the panel rules do not appear

Because an inspection and a label review are different acts. An investigator walks your facility and reads your records against the manufacturing rule. Whether your ingredient list is in descending order of predominance is not answered by anything in your building. It is answered by reading the panel, which a compliance officer does later, from a specimen. That reading is written up as misbranding, not as an inspection observation.

So the two halves fail differently. A panel error surfaces when somebody reads your label — a competitor, a marketplace, a compliance officer. A control failure surfaces when somebody walks in. Neither closes the other.

Four things to check before you spend

Take dated copies before you change anything. A label specification and a master manufacturing record are controlled records, and revising one is your own quality unit’s decision, not a tidy-up.

1. Run the panel list above against your artwork, and treat it as a starting set rather than a complete one. This is the part you can do yourself and the part a generator does reasonably well.
2. Open your master manufacturing record and look for the label. A description of the packaging and a representative label, or a cross-reference to where the real one is kept. That clause carries 128 observations.
3. Ask for the written labeling procedure — not the artwork file, the procedure for packaging and labeling operations.
4. Ask how the right label is shown to have gone on this batch. The clause that asks for that examination is 111.410(c), and the answer should be a record rather than an assurance that everyone knows.

Related reading: who is supposed to build the label content, you or your manufacturer, and which rule reaches each of you.